NCT05999994 2026-03-27
CAMPFIRE
Eli Lilly and Company
Phase 2 Recruiting
Clinical Trials
6 trialsNCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT06043713 2025-12-19
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations
Fred Hutchinson Cancer Center
Phase 1 Recruiting
NCT06415487 2025-07-01
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
Acepodia Biotech, Inc.
Phase 1 Recruiting
NCT05141474 2024-11-07
NEXTGENTIL-ACT
Vall d'Hebron Institute of Oncology
Phase EARLY_PHASE1 Recruiting
NCT06013111 2024-02-21
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors
China Medical University, China
Phase 1 Recruiting